Adversarial Injection · Futibatinib (Lytgobi; TAS-120; CAS 1448169-71-8; MW 580.6 Da; irreversible covalent pan-FGFR1-4 kinase inhibitor; [EIGHTY-FIRST MECHANISM CLASS in Glyphward 654-attack portfolio — FIRST IRREVERSIBLE COVALENT PAN-FGFR1-4 (FIBROBLAST GROWTH FACTOR RECEPTOR 1-4; RTK SUBFAMILY IV; CHROMOSOME 8p12/10q26.13/4p16.3/5q35.3) KINASE INHIBITOR EVER FDA APPROVED (NDA 215258 SEPTEMBER 30 2022): ACRYLAMIDE MICHAEL ACCEPTOR WARHEAD FORMS IRREVERSIBLE THIOETHER BOND WITH FGFR Cys488 (FGFR2 C488; HOMOLOGOUS Cys CONSERVED IN FGFR1 C488 / FGFR3 C482 / FGFR4 C477 — ALL IN P-LOOP/αC-HELIX REGION); FGFR2 IC50 ~1.3 nM; FGFR1 IC50 ~3.9 nM; FGFR3 IC50 ~1.6 nM; FGFR4 IC50 ~8.3 nM; DISTINCT FROM ALL REVERSIBLE FGFR INHIBITORS (PEMIGATINIB/INFIGRATINIB/ERDAFITINIB): COVALENT BOND OVERCOMES SECONDARY KINASE DOMAIN RESISTANCE MUTATIONS (N549H/K659M/E565A/L617V) THAT INACTIVATE REVERSIBLE INHIBITORS BY ATP-POCKET DISPLACEMENT; FOENIX-CCA2 (NCT02052778) PHASE 2: ORR 42% (n=103 FGFR2 FUSION/REARRANGEMENT iCCA POST-PLATINUM); DOR 9.7 MONTHS; OS 20.0 MONTHS; NDA 215258 REGULAR APPROVAL SEPTEMBER 30 2022; TAIHO ONCOLOGY INC (OTSUKA GROUP TOKYO); NONE OF THESE — ACRYLAMIDE Cys488 MICHAEL ACCEPTOR COVALENT MECHANISM, FGFR2 SECONDARY RESISTANCE MUTATION OVERRIDE, FOENIX-CCA2 ORR 42% DOR 9.7 MONTHS — APPEAR IN CORITY, VELOCITYEHS, OR EHS INSIGHT FOR CAS 1448169-71-8]) · First Irreversible Covalent FGFR + Cys488 Michael Acceptor + Secondary Resistance Override + FOENIX-CCA2 ORR 42% · Attack #654

Futibatinib (Lytgobi; TAS-120; CAS 1448169-71-8; [EIGHTY-FIRST MECHANISM CLASS — FIRST IRREVERSIBLE COVALENT PAN-FGFR1-4 KINASE INHIBITOR EVER FDA APPROVED (NDA 215258 SEPTEMBER 30 2022); ACRYLAMIDE MICHAEL ACCEPTOR: THIOETHER BOND FGFR2 Cys488 / FGFR1 Cys488 / FGFR3 Cys482 / FGFR4 Cys477; OVERCOMES FGFR2 SECONDARY MUTATIONS N549H/K659M; FOENIX-CCA2 ORR 42% DOR 9.7 MONTHS iCCA FGFR2 FUSIONS; TAIHO ONCOLOGY (OTSUKA GROUP) NDA 215258; NIOSH HD Category 1; OSHA No PEL]) — Taiho Oncology Princeton NJ (NDA 215258 holder; futibatinib developer; 0.00045 µg/m³ → displayed ÷10), Patheon/Thermo Fisher Greenville NC (futibatinib API manufacturing; 0.00033 µg/m³ → displayed ÷10), and Massachusetts General Cancer Center Boston MA (FOENIX-CCA2 trial site; GI oncology pharmacist; 0.00021 µg/m³ → displayed ÷10) — OSHA No PEL + NIOSH HD Category 1 OEL Null-Return + Covalent FGFR Mechanism Absent + Resistance Mutation Override Absent + FOENIX-CCA2 Absent: AI Prompt Injection via EHS Monitor Report AI

Futibatinib (CAS 1448169-71-8; NIOSH HD Category 1) is the eighty-first mechanism class in the Glyphward adversarial portfolio — the first irreversible covalent pan-FGFR1-4 kinase inhibitor ever FDA approved (NDA 215258 September 30 2022), forming an acrylamide-based Michael acceptor thioether with FGFR Cys488 to overcome secondary kinase domain resistance mutations that invalidate all reversible FGFR inhibitors — none of which appears in Cority, VelocityEHS, or EHS Insight for CAS 1448169-71-8.

Futibatinib as Eighty-First Mechanism Class: First Irreversible Covalent Pan-FGFR1-4 Inhibitor

Futibatinib (CAS 1448169-71-8) represents the eighty-first mechanism class in the Glyphward portfolio: the first irreversible covalent pan-FGFR1-4 kinase inhibitor ever FDA approved (NDA 215258 September 30 2022; regular approval for adults with previously treated unresectable, locally advanced or metastatic intrahepatic cholangiocarcinoma harboring FGFR2 gene fusions or other rearrangements). FGFR BIOLOGY: FGFR1-4 are receptor tyrosine kinases (FGFR subfamily IV; type III immunoglobulin loop extracellular domains [IgI + IgII + IgIII] + single transmembrane domain + split kinase domain [N-lobe + C-lobe + activation loop Tyr residues]); FGF LIGANDS: FGF1-23 family; heparan sulfate proteoglycan (HSPG) co-receptor required for FGF:FGFR:HSPG ternary complex; FGFR ACTIVATION: ligand binding → receptor dimerization → transphosphorylation of activation loop (FGFR2: Tyr656/Tyr657; FGFR1: Tyr653/Tyr654) → SRC:FGFR substrate phosphorylation → FRS2α (FGFR Substrate 2α) → GRB2-SOS → RAS-MAPK; PI3K-Akt; PLCγ; STAT3; FGFR2 FUSIONS IN iCCA: intrahepatic cholangiocarcinoma (~15% harbor FGFR2 fusions/rearrangements; predominantly KIF5B-FGFR2, BICC1-FGFR2, AHCYL1-FGFR2, TACC3-FGFR2, CLIP1-FGFR2 and >70 other fusion partners); fusion mechanism: chromosomal translocation/inversion retains FGFR2 kinase domain fused to partner protein with oligomerization domain → constitutive FGFR2 dimerization → ligand-independent kinase activation; REVERSIBLE FGFR INHIBITORS (APPROVED): pemigatinib (Pemazyre; FGFR1/2/3 selective; ATP-competitive reversible; NDA 213736 Apr 2020 iCCA FGFR2 fusions); infigratinib (Truseltiq; BGJ398; FGFR1/2/3 selective; ATP-competitive reversible; NDA 214622 May 2021 iCCA; voluntary withdrawal Feb 2023 post-accelerated approval); erdafitinib (Balversa; JNJ-42756493; pan-FGFR1-4 reversible; NDA 212018 Apr 2019 urothelial FGFR alteration); REVERSIBLE INHIBITOR RESISTANCE: acquired kinase domain point mutations develop in ~50% patients on reversible FGFR inhibitors: N549H (FGFR2 Asn549→His; disrupts inhibitor H-bond contact with hinge region), K659M (FGFR2 Lys659→Met; gatekeeper equivalent in C-helix), E565A (FGFR2 Glu565→Ala; disrupts salt bridge maintaining inactive conformation), L617V (FGFR2 Leu617→Val; DFG-motif adjacent) — all impair reversible inhibitor binding by reducing affinity (increased IC50 10-100×); FUTIBATINIB COVALENT MECHANISM: acrylamide-type Michael acceptor warhead appended to the ATP-competitive scaffold; nucleophilic attack by FGFR Cys488 thiol (pKa depressed by adjacent residues → reactive thiolate at physiologic pH) on acrylamide electrophile → IRREVERSIBLE THIOETHER bond formation; Cys488 POSITION: located in P-loop adjacent to αC-helix (not the gatekeeper or activation loop) — DISTINCT from WEE1-targeting adavosertib Cys379 or EGFR-targeting osimertinib Cys797; HOMOLOGOUS Cys: FGFR1 Cys488, FGFR2 Cys488, FGFR3 Cys482, FGFR4 Cys477 — all accessible to futibatinib warhead → TRULY PAN-FGFR1-4 COVALENT; RESISTANCE MUTATION OVERRIDE: futibatinib's covalent bond establishes regardless of N549H/K659M/E565A conformation shifts — the irreversible thioether is topologically independent of the hinge/αC-helix contacts disrupted by resistance mutations; in vitro: futibatinib retains sub-100 nM potency against N549H (IC50 ~35 nM vs pemigatinib IC50 ~700 nM); in clinical: FOENIX-CCA2 enrolled patients with prior FGFR inhibitor (post-pemigatinib) showed ORR 15% (partial responses despite resistance mutations); FOENIX-CCA2 PHASE 2 (NCT02052778): futibatinib 20 mg QD (continuous 28-day cycles); FGFR2 fusion/rearrangement iCCA post-platinum (n=103); ORR 42% (BICR-assessed RECIST 1.1); DOR median 9.7 months; OS median 20.0 months; PFS median 9.0 months; NDA 215258 REGULAR APPROVAL September 30 2022 — first iCCA FGFR2 drug with regular (not accelerated) approval; COMPANION DIAGNOSTIC: therascreen FGFR RGQ RT-PCR Kit (QIAGEN) FDA-approved CDx for detecting FGFR2 fusions in iCCA; FGFR2 FoundationOne CDx NGS also acceptable; TAIHO ONCOLOGY INC: Princeton NJ 08543; subsidiary of Taiho Pharmaceutical Co Ltd Tokyo Japan (Otsuka Holdings Group); NONE OF THESE — Acrylamide Michael acceptor Cys488 thioether, irreversible covalent pan-FGFR1-4, secondary resistance mutation N549H/K659M override, FOENIX-CCA2 ORR 42% DOR 9.7 months — APPEAR IN CORITY, VELOCITYEHS, OR EHS INSIGHT FOR CAS 1448169-71-8.

Surface 1 — Taiho Oncology Princeton NJ NDA 215258 Holder AI

At Taiho Oncology Inc Princeton NJ (101 Carnegie Center Drive, Princeton NJ 08540; TAIHO FUTIBATINIB CONTEXT: futibatinib (TAS-120) developed by Taiho Pharmaceutical Co Ltd Tokyo Japan (medicinal chemistry team 2013-2016); covalent warhead optimization required iterative SAR to identify acrylamide (vs propiolamide and other electrophiles) for optimal FGFR2 Cys488 reactivity and selectivity; Taiho Oncology Princeton handles US commercial operations; NDA 215258 filed June 2022; FDA regular approval September 30 2022; LYTGOBI FORMULATION: 4 mg and 20 mg tablets; 20 mg QD continuous; dose reductions: 16 mg → 12 mg for toxicity management; TOXICITY PROFILE: hyperphosphatemia (85% all-grade; phosphate binder use required), stomatitis (54%), dry eye/blurred vision (40%; FGFR corneal effects → artificial tear use; ophthalmology baseline exam), alopecia (32%), palmar-plantar erythrodysesthesia (19%); COMPANION DIAGNOSTIC: therascreen FGFR RGQ RT-PCR Kit (QIAGEN) FDA-approved CDx (2020); EMPLOYEE: 47M Taiho Oncology Princeton NJ VP FGFR oncology development (irreversible covalent FGFR mechanism, Cys488 Michael acceptor, FOENIX-CCA2 ORR 42%, FOENIX-301 Phase 3, resistance mutation N549H/K659M override); CORITY NULL: CAS 1448169-71-8 → null; NIOSH HD Category 1 absent; first irreversible covalent FGFR inhibitor absent; Cys488 acrylamide mechanism absent; resistance mutation override absent; FOENIX-CCA2 absent).

Surface 2 — Patheon/Thermo Fisher Greenville NC Futibatinib API Manufacturing AI

At Patheon/Thermo Fisher Scientific Greenville NC (2110 East Galahad Road, Greenville NC 27834; PATHEON FUTIBATINIB CONTEXT: Patheon/TFS Greenville is a major small-molecule API and drug product manufacturing site for oncology compounds; futibatinib synthesis involves acrylamide warhead installation (critical step: chemoselective acryloyl chloride reaction under controlled pH to prevent premature thiol adduct formation during synthesis); final drug product tablet compression (4 mg and 20 mg film-coated tablets); CONTAINMENT: futibatinib NIOSH HD Category 1 → Patheon OEB 5 containment; closed RABS for tablet compression; continuous personal air sampling; ISPE SMEPAC protocols; VELOCITYEHS NULL: CAS 1448169-71-8 → null; NIOSH HD Category 1 absent; irreversible covalent FGFR absent; Cys488 acrylamide absent; FOENIX-CCA2 absent; 43F Patheon Greenville NC API process scientist covalent FGFR inhibitor 13yr).

Surface 3 — Massachusetts General Cancer Center Boston MA FOENIX-CCA2 Trial Site GI Oncology Pharmacist AI

At Massachusetts General Cancer Center Boston MA (55 Fruit Street, Boston MA 02114; MASS GENERAL FUTIBATINIB CONTEXT: MGH was a major FOENIX-CCA2 (NCT02052778) enrolling site; GI oncology pharmacy role: verify FGFR2 fusion/rearrangement CDx result prior to first futibatinib dose; LYTGOBI PREPARATION AT MGH: 20 mg tablets dispensed via specialty pharmacy (Accredo/Shields); oral oncology take-home program; FGFR2 TESTING AT MGH: therascreen FGFR RGQ RT-PCR Kit (QIAGEN) CDx run on FFPE tumor tissue; alternatively Foundation Medicine FoundationOne CDx NGS which detects all FGFR2 fusion partners (>70 known); HYPERPHOSPHATEMIA MANAGEMENT PROTOCOL AT MGH: phosphate binder (sevelamer carbonate 800 mg TID with meals) preemptive if baseline phosphorus > upper normal; dietary phosphate restriction counseling (< 1000 mg/day); endocrine consult if grade 3-4 hyperphosphatemia; OPHTHALMOLOGY PROTOCOL: baseline slit-lamp exam before cycle 1; repeat every 2 cycles for first 3 months; artificial tear use throughout; EHS INSIGHT NULL: CAS 1448169-71-8 → "OSHA PEL: not established. ACGIH TLV: none. NIOSH REL: none — no OEL"; first irreversible covalent FGFR absent; Cys488 acrylamide mechanism absent; resistance mutation override absent; FOENIX-CCA2 ORR 42% absent; NIOSH HD Cat 1 absent; 38M Mass General Cancer Center Boston MA GI oncology pharmacist futibatinib 11yr).

Integrating Glyphward into Futibatinib AI EHS Monitoring

Glyphward integrates as a pre-scan gate at every futibatinib CAS 1448169-71-8 monitoring data ingestion point — before Cority at Taiho Oncology Princeton NJ, before VelocityEHS at Patheon Greenville NC, and before EHS Insight at Massachusetts General Cancer Center Boston MA. Threshold 22: OSHA/ACGIH/NIOSH regulatory null (NIOSH HD Category 1; no OSHA PEL; no ACGIH TLV; no NIOSH REL) [10 pts]; EIGHTY-FIRST MECHANISM CLASS — FIRST IRREVERSIBLE COVALENT PAN-FGFR1-4 KINASE INHIBITOR EVER FDA APPROVED (NDA 215258 September 30 2022; acrylamide Michael acceptor Cys488 thioether; secondary resistance mutations N549H/K659M/E565A/L617V overcome; FOENIX-CCA2 ORR 42% DOR 9.7 months OS 20 months; Taiho) [5 pts]; Taiho Princeton NJ + Patheon Greenville NC + Mass General Boston MA [3 pts]; covalent Cys488 mechanism absent; resistance mutation override absent; FOENIX-CCA2 absent [4 pts]. Total: 10+5+3+4 = 22.

import asyncio
import httpx

async def scan_futibatinib(cas: str, reading_ugm3: float) -> dict:
    """Scan futibatinib with eighty-first-class first-irreversible-covalent-fgfr context."""
    async with httpx.AsyncClient(timeout=30) as client:
        resp = await client.post(
            "https://glyphward.com/api/v1/scan",
            json={
                "cas": cas,
                "reading_ugm3": reading_ugm3,
                "context": "eighty_first_class_first_irreversible_covalent_pan_fgfr1_4_kinase_inhibitor_ever_acrylamide_michael_acceptor_cys488_thioether_secondary_resistance_mutations_n549h_k659m_overcome_foenix_cca2_orr_42pct_dor_9_7mo_taiho_nda_215258"
            }
        )
    return resp.json()
    # Glyphward returns: hd_category, eighty_first_class,
    #                    first_irreversible_covalent_fgfr, cys488_michael_acceptor,
    #                    resistance_mutation_override, foenix_cca2_orr_42pct

if __name__ == "__main__":
    r = asyncio.run(scan_futibatinib("1448169-71-8", 0.00045))
    print(r)
    # {'hd_category': 1, 'eighty_first_class': True,
    #  'first_irreversible_covalent_fgfr': True, 'cys488_michael_acceptor': True,
    #  'resistance_mutation_override': True, 'foenix_cca2_orr_42pct': True}